Chronic cerebrovascular diseases and metabolic syndrome: approaches to pathogenic therapy of cognitive dysfunction

Close metadata

Recommended articles:

The use of Mexidol in patients with mild (moderate) cognitive impairment: results of a meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(1):82-88

Multi-center open comparative randomized study of efficacy and safety of Akatinol Memantine 20 mg (single-doses) vs Akatinol Memantine 10 mg (double-doses) in patients with vascular dementia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):69-77

Treatment of patients with ishemic stroke in the vertebral-basilar system in acute period: experience of using the neuroprotective drug Mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):78-84

Cerebral amyloid angiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):85-90

Psychopharmacotherapy of mixed affective states in bipolar disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):103-108

The relationship between the development of post-stroke cognitive impairment and changes in the coagulation component of hemostasis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):23-29

The effect of insomnia on mild cognitive impairment in patients with vascular risks: results of a three-year longitudinal study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):30-36

Bilirubin is a promising target for metabolic and atherosclerotic cardiovascular diseases. Russian Journal of Preventive Medicine. 2024;(1):121-127

Influence of nitric oxide metabolites and markers of apoptosis on restenosis of the reconstruction zone after hybrid interventions. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(1):14-21

Lipoprotein(a) and triglyceride-rich lipoproteins — association with recurrent nonfatal myocardial infarction in patients with early manifestation of coronary artery disease. Russian Cardiology Bulletin. 2024;(1):29-37

Cognitive decline comprises one of the most important symptoms of chronic cerebral hypoperfusion. It leads not only to social disability of the patients with a subsequent decline in life quality but also to a decrease in adequate control of the course of both vascular pathology and comorbid states. Pathogenetic therapy and prevention of cerebrovascular disease progression, along with general medical measures, should include the drugs normalizing different symptoms of metabolic syndrome (arterial hypertension, diabetes mellitus etc) as well as complex drugs with multiple actions (hemangioma correction, antithrombotic, antioxidant and vasoactive) actions.

Keywords:

cerebrovascular disease

metabolic syndrome

atherosclerosis

cognitive disorders

pathogenic therapy

Authors:

Tanashyan M.M.

Neurology Research Center, Moscow, Russia

Lagoda O.V.

Research Centre of Neurology, Moscow, Russia

Antonova K.V.

Neurology Research Center, Moscow, Russia

Konovalov R.N.

Nauchnyĭ tsentr nevrologii RAMN, Moskva

List of references:

Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive Summary: Heart Disease and Stroke Statistics-2012 Update: A Report From the American Heart Association. Circulation. 2012;125:188-197. doi: 10.1161/CIR.0b013e3182456d46
Stahovskaja LV, Klochihina OA, Bogatyreva MD, Kovalenko VV. Jepidemiologija insul'ta v Rossii po rezul'tatam territorial'no-populjacionnogo registra (2009—2010). Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2013;113(5):4-10. (In Russ.).
Estol C. Atherosclerosis: The XXIst Century Epidemic: A Meeting at the Vatican. Stroke. 2011;42(12):3338-3339. doi: 10.1161/strokeaha.111.640300
Bakker F, Klijn C, Jennekens-Schinkel A, Kappelle L. Cognitive disorders in patients with occlusive disease of the carotid artery: a systematic review of the literature. Journal of Neurology. 2000;247(9):669-676. doi: 10.1007/s004150070108
Suslina ZA, Tanashjan MM, Lagoda OV. Ateroskleroz i ishemicheskie narushenija mozgovogo krovoobrashhenija. Aterotromboz. 2009;2(3):60-67. (In Russ.).
Deedwania PC. Metabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease? Circulation. 2004;109:2-41. doi: 10.1161/01.CIR.0000110642.73995.BF
Antonini-Canterin F, La Carrubba S, Gullace G et al. Associacion Between Carotid Atherosclerosis and Metabolic Syndrome: Results From the ISMIR Study. Angiology. 2010;61(5):443-448. doi: 10.1177/0003319709360523
Maksimovic M, Vlajinac H, Radak D, Maksimovic J, Otasevic P et al. Frequency and characteristics of metabolic syndrome in patients with symptomatic carotid atherosclerosis. Rev Med Chile. 2009;137:329-336. doi: S0034-98872009000300002
Preobrazhenskaja IS, Jahno NN. Vozrastnaja kognitivnaja disfunkcija: diagnostika i lechenie. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2006;11(106):33-38. (In Russ.).
Cerebrovascular disease, cognitive impairment and dementia. Second edition of Cerebrovascular disease and dementia. Ed. by O'Brien J, Ames D., Gustafson L., Folstein M., Chie E. Martin Dunitz. 2004.
Zaharov VV. Jevoljucija kognitivnogo deficita: legkie i umerennye kognitivnye narushenija. Nevrologija, nejropsihiatrija, psihosomatika. 2012;2:16-21. (In Russ.).
Shprah VV, Sajutina SB, Romazina TA. Lechenie kognitivnyh narushenij pri serdechno-sosudistyh zabolevanijah. Metodicheskie rekomendacii. Irkutsk: RIO IGIUVa; 2009. (In Russ.).
Jahno NN, Zaharov VV, Sosina VB. Nedementnye kognitivnye narushenija u bol'nyh saharnym diabetom 2-go tipa. Nevrologicheskij zhurnal. 2010;4:25-30. (In Russ.).
Cosentino F, Battista, MD R, Scuteri A et al. Impact of Fasting Glycemia and Regional Cerebral Perfusion in Diabetic Subjects. Stroke. 2009;40:306-308. doi: 10.1161/STROKEAHA.108.520627
Raffaitin C, Féart C, Le Goff M, Amieva H, Helmer C, Akbaraly TN, Tzourio C, Gin H, Barberger-Gateau P. Metabolic syndrome and cognitive decline in French elders: the Three-City Study. Neurology. 2011;76(6):518-525. doi: 10.1212/WNL.0b013e31820b765:1526-632X
Tanashjan MM, Lagoda OV, Orlov SV, Telenkova NG, Maksjutkina LN, Petruhina SJu. Sosudistye zabolevanija golovnogo mozga i metabolicheskij sindrom. i 2013;10(85):34-42. (In Russ.).
Lebedeva NV, Zareckaja IH, Kozlova EN i dr. Primenenie preparata kavinton v medicinskoj praktike. M. 1979. (In Russ.).
Kozlova EN, Usman VB, Lobkova TN. Primenenie kavintona dlja lechenija sosudistyh zabolevanij golovnogo mozga s uchetom vozrastnyh osobennostej. M. 1983. (In Russ.).
Lebedeva NV. Znachenie preparata kavinton v lechenii bol'nyh s ostroj i hronicheskoj sosudistoj mozgovoj nedostatochnost'ju. Kavinton i vozmozhnosti ego primenenija v medicinskoj praktike. M. 1986. (In Russ.).
Suslina ZA, Tanashjan MM, Maksimova MJu, Kistenev BA, Ionova VG, Sharypova TN. Kavinton (vinpocetin) v lechenii bol'nyh s ostrymi i hronicheskimi formami sosudistyh zabolevanij golovnogo mozga: novye aspekty terapii. Farmateka. 2004;14:99-104. (In Russ.).
Nagy Z, Vargha P, Kovacs L et al. Metaanalysis of cavinton. Praxis. 1998;7:63-68.
Hindmarch I, Fuchs H, Erzigkeit H. Efficacy and Tolerance of Vinpocetine in Ambulant Patients Suffering from Mild to Moderate Organic Psychosyndromes. Int Clin Psychopharmacology. 1991;6(1):31-44. doi: 10.1097/00004850-199100610-00005
Zhivolupov SA, Samarcev IN, Jakovlev EV, Butakova JuS, Bodrova TV. Ocenka jeffektivnosti vinpocetina (kavintona komforte) v lechenii golovokruzhenija u pacientov s discirkuljatornoj jencefalopatiej po urovnju nejrotroficheskogo faktora mozga (BDNF) v plazme krovi. Klinicheskaja farmakologija i terapija. 2016;25(1):49-54. (In Russ.).
Suslina ZA, Tanashjan MM, Ionova VG, Kistenev BA, Maksimova MJu, Sharypova TN. Kavinton v lechenii bol'nyh s ishemicheskimi narushenijami mozgovogo krovoobrashhenija — novye aspekty dejstvija. Lechenie nervnyh boleznej. 2002;3(3):19-24. (In Russ.).
Tanashjan MM, Lagoda OV, Fedin PA, Konovalov RN, Rodionova JuV, Suslina ZA. Primenenie vinpocetina dlja lechenija kognitivnyh narushenij u bol'nyh s hronicheskimi cerebrovaskuljarnymi zabolevanijami. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2007;107:10:41-43. (In Russ.).
Tanashjan MM, Lagoda OV, Fedin PA, Konovalov RN, Rodionova JuV. Sovremennye podhody k lecheniju bol'nyh s hronicheskimi sosudistymi zabolevanijami golovnogo mozga. Atmosfera. Nervnye bolezni. 2010;4:19-22. (In Russ.).

Close metadata